Received Feb 13, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | UNK | C2Y9B | RA |
20-year-old female received an Engerix B Pediatric/Adolescent Vaccine dose; 20-year-old female received an Engerix B Pediatric/Adolescent Vaccine dose; This non-serious case was reported by a other health professional via call center representative and described the occurrence of underdose in a 20-year-old female patient who received HBV (Engerix B pediatric) (batch number C2Y9B, expiry date 15-JUL-2026) for prophylaxis. On 08-JAN-2025, the patient received Engerix B pediatric (right arm) .5 ml. On 08-JAN-2025, an unknown time after receiving Engerix B pediatric, the patient experienced underdose (Verbatim: 20-year-old female received an Engerix B Pediatric/Adolescent Vaccine dose) and adult use of a child product (Verbatim: 20-year-old female received an Engerix B Pediatric/Adolescent Vaccine dose). The outcome of the underdose and adult use of a child product were unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 17-JAN-2025 The other health professional reported that a 20-year-old female patient received an Engerix B Pediatric/Adolescent vaccine dose instead of Engerix B 20 adult dose by error which led to underdose and adult use of child product. The other health professional stated that the vaccine was administered on the right arm. No additional information was provided.